Supply Sitagliptin Phosphate Monohydrate Related Intermediates:
Sitagliptin API CAS 486460-32-6
Sitagliptin Phosphate Monohydrate API CAS 654671-77-9
2,4,5-Trifluorophenylacetic Acid CAS 209995-38-0
Boc-(R)-3-Amino-4-(2,4,5-Trifluoro-Phenyl)-Butyric Acid CAS 486460-00-8
Sitagliptin Triazole Hydrochloride CAS 762240-92-6
Sitagliptin Phosphate Monohydrate Intermediate CAS 486460-21-3
| Chemical Name | Sitagliptin Phosphate Monohydrate |
| Synonyms | (R)-3-amino-1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-4-(2,4,5-trifluorophenyl)butan-1-one phosphate monohydrate |
| CAS Number | 654671-77-9 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C16H20F6N5O6P |
| Molecular Weight | 523.3240802 |
| Melting Point | 202.0~204.0℃ |
| Water Solubility | Soluble in Water |
| Specific Rotation | -18.0°~-23.0° (C=1, Water) |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Appearance | White to Off-White Crystalline Powder |
| Identification by HPLC | The retention time of sample is concordant with reference standard |
| IR-Infrared Spectrum | The IR Absorption Spectrum of the sample shall be concordant with that of standard spectrum |
| Phosphate | Complies |
| Purity / Analysis Method | >99.0% (HPLC on the dried basis) |
| Water Content (K.F) | 3.3%~4.4% |
| Residue on Ignition | ≤0.20% |
| Sulphate | ≤0.02% |
| Chloride | ≤0.05% |
| Chiral Impurity | <0.50% |
| Related Substances | |
| Single Impurity | <0.50% |
| Total Impurities | <1.0% |
| Ethyl Acetate | <0.50% |
| Heavy Metals | <20ppm |
| Test Standard | Enterprise Standard |
| Usage | Pharmaceutical Intermediates |
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.
Sitagliptin Phosphate Monohydrate (CAS: 654671-77-9), a new drug for the treatment of type 2 diabetes. In August 2009, the drug was approved by the European Union as a first-line drug for the treatment of type 2 diabetes. Sitagliptin Phosphate is the first FDA-approved dipeptidyl peptidase-IV inhibitor to be used in the treatment of type 2 diabetes by far, under the trade name Januvia. Dipeptidylpeptidase Ⅳ (DPP-Ⅳ) rapidly and effectively degrades GLP-1, GLP-1, which is the most effective stimulator of insulin production and secretion Therefore, inhibition of DPP-IV can enhance the role of endogenous GLP-1, thereby increasing blood insulin levels, thereby reducing and maintaining blood glucose levels in diabetic patients. At present, medicine has confirmed that DPP-IV inhibitor is a new type of anti-diabetic drug, and clinical results show that the drugs have a good hypoglycemic effect. Because GLP-1 plays a glucose-dependent role in promoting insulin production and secretion, common adverse reactions such as hypoglycemia and weight gain caused by the use of antidiabetic drugs do not occur.